In this weeks video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not yet been reduced.
BOTTOM LINE:
The cost of drugs is important to all of the myeloma community, and the IMF will continue to take part in discussing this.
Advertisement